Industry News
Share your love
NCX 470 advances toward US, China NDA submissions for NCX 470 | Ophthalmology Times
(Image Credit: AdobeStock) Nicox has announced it has acquired and analyzed all key data required to support the submission of New Drug Applications (NDAs) in the US and China for NCX 470.1 NCX 470 is Nicox’s lead clinical product candidate…
Unmet Needs in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Management and Monitoring Strategies in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Spotlight on women’s health: Understanding thyroid eye disease | Ophthalmology Times
Image by Jennifer Toomey/MJH Life Sciences using AI Thyroid eye disease (TED), also known as Graves ophthalmopathy or Graves eye disease, is an autoimmune condition in which the immune system targets tissues related to the thyroid.1 This leads to inflammation…
FDA extends Aldeyra’s reproxalap PDUFA after requesting additional clinical study report | Ophthalmology Times
(Image Credit: AdobeStock) The US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for Aldeyra’s New Drug Application (NDA) for reproxalap for the treatment of dry eye disease (DED). The new…
Managing challenging pterygium removal: Amniotic membrane grafting strategies | Ophthalmology Times
(Image Credit: AdobeStock/Sangiao_Photography) Pterygium is a common ocular surface disorder characterized by a fibrovascular growth originating from the conjunctiva that extends onto the adjacent cornea (Figure).1 Its prevalence varies considerably across geographic regions. Because prolonged sun exposure is the main…
Aviceda Therapeutics reports positive phase 2b SIGLEC results for AVD-104 in geographic atrophy | Ophthalmology Times
(Image Credit: AdobeStock/9dreamstudio) Aviceda Therapeutics has released topline results from its phase 2b study, SIGLEC, evaluating AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). AVD-104 is a polysialic acid-coated nanoparticle in which the polysialic acid…
Advantages of Neurogenic Stimulation and Identifying Ideal Dry Eye Candidates for Acoltremon | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
The Role of TRPM8 Agonists in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA | Ophthalmology Times
(Image Credit: AdobeStock) Inflammasome Therapeutics has completed enrollment in a multicenter phase 2 dose-ranging trial (NCT06164587) for its dual inflammasome inhibitor, K8, for geographic atrophy (GA). K8 is a member of a new class of inflammasome-inhibiting drugs called Kamuvudines. They…